Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus

Yagi, Shusuke; Aihara, Ken‐ichi; Kondo, Takeshi; Kurahashi, Kiyoe; Yoshida, Sumiko; Endo, Itsuro; Fukuda, Daiju; Nakaya, Yutaka; Suwaki, Kinichiro; Takeji, Takashi; Wada, Toshihiro; Salim, Hotimah Masdan; Hama, Saori; Matsuura, Tomomi; Ise, Takayuki; Kusunose, Kenya; Yamaguchi, Koji; Tobiume, Takeshi; Yamada, Hirotsugu; Soeki, Takeshi; Wakatsuki, Tetsuzo; Matsuhisa, Munehide; Shimabukuro, Michio; Akiyama, Masashi; Sata, Masataka

doi:10.1007/s12325-017-0639-z

Cited by 13 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The decreased HbA1c levels were associated with improvement in the liver function. Consistent with previous studies [10] , [11] , [12] , SGLT2 inhibitors decreased the HbA1c levels regardless of the baseline BMI. Moreover, we propose the novel use of 1,5-AG in predicting the hypoglycemic effect of SGLT2 inhibitors.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 diabetes mellitus

Usui

Tanaka

Takahashi

2020

Journal of Clinical & Translational Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

“…1,5-AG remained the most beneficial factor after the multivariate analysis. 1,5-AG has detective ability more useful for patients than HbA1c value or eGFR value, which was previously reported [12] .…”

Section: Discussionmentioning

confidence: 56%

1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 diabetes mellitus

Usui

Tanaka

Takahashi

2020

Journal of Clinical & Translational Endocrinology

View full text Add to dashboard Cite

show abstract

“…Considering these results, an SGLT2i was frequently added to the regimens of obese patients in our study. Additionally, it has been reported that the efficacy of SGLT2is is greater in patients with preserved renal function than in those without preserved renal function [22,23]. In our study, the SGLT2i add-on group demonstrated higher eGFR than the other two groups.…”

Section: Discussionsupporting

confidence: 54%

Clinical Efficacy of Quadruple Oral Therapy for Type 2 Diabetes in Real-World Practice: A Retrospective Observational Study

et al. 2020

View full text Add to dashboard Cite

Introduction: We aimed to evaluate the effectiveness of quadruple oral therapy in patients with inadequately controlled type 2 diabetes (T2D) with the use of three types of oral hypoglycemic agents. Methods: Medical records of 318 patients with T2D who were prescribed quadruple therapy in the Asan Medical Center were reviewed. Changes in glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) levels from baseline were assessed. The regimens of quadruple oral therapy included the following: (1) thiazolidinedione (TZD) add-on to metformin (MET) ? sulfonylurea (SU) ? dipeptidyl peptidase 4 inhibitor (DPP4i), (2) sodium-glucose cotransporter 2 inhibitor (SGLT2i) add-on to MET ? SU ? DPP4i, and (3) DPP4i add-on to MET ? SU ? TZD. Results: The TZD add-on significantly reduced HbA1c levels by 1.1% (from 9.0 ± 1.1 to 7.9 ± 1.1%, P \ 0.001) and FPG levels by 41.4 mg/dL (from 188.9 ± 45.9 to 147.4 ± 51.3 mg/dL, P \ 0.001). The SGLT2i add-on changed the mean HbA1c level from 8.9 ± 1.0 to 7.8 ± 1.0%, a reduction of 1.1% (P \ 0.001) and changed the mean FPG level from 193.4 ± 46.2 to 152.6 ± 37.0 mg/dL, a reduction of 40.8 mg/ dL (P \ 0.001). Finally, the DPP4i add-on reduced HbA1c levels by 1.3% (from 9.1 ± 1.3 to 7.8 ± 1.4%, P \ 0.001) and FPG levels by 39.3 mg/dL (from 190.7 ± 45.3 to 151.4 ± 41.6 mg/dL, P \ 0.001). Patients with higher baseline HbA1c levels (C 9.0%) showed a better response to quadruple therapy than those with baseline HbA1c levels lower than 9.0% for all three regimens. Conclusion: Quadruple oral hypoglycemic therapy can be a feasible option in patients with T2D.

show abstract

“…Previous RCTs have reported that the decreases of HbA1c were −0.50% to 0.80% from a baseline of 7.90% to 9.20% after the administration of DAPA [1415161718]. The effect of DAPA was affected by baseline HbA1c level and eGFR [19]. Our patients' baseline HbA1c level was not higher than that of previous trials.…”

Section: Discussioncontrasting

confidence: 56%

Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea

Park

Choi²,

Rhee

et al. 2019

Endocrinol Metab

View full text Add to dashboard Cite

BackgroundWe aimed to retrospectively analyze the efficacy of 10 mg dapagliflozin (DAPA), which is a sodium-glucose cotransporter-2 inhibitor, in Korean patients with type 2 diabetes who visited a primary diabetes clinic.MethodsIn total, 83 patients with type 2 diabetes, who received treatment with DAPA for the first time in a primary diabetes clinic between January 2015 and October 2015, were included in the study. The effect of DAPA in lowering glycosylated hemoglobin (HbA1c) levels was evaluated via chart review at 6 months follow-up. The patients were categorized into five groups according to add-on to or switched from other glucose-lowering agents: add-on to metformin (MET, n=10), add-on to MET+dipeptidyl peptidase 4 inhibitor (DPP4i, n=12), switched from sulfonylurea (SU, n=13), switched from DPP4i (n=11), and switched from thiazolidinedione (TZD, n=37). All the participants had already used MET for their regimen.ResultsTreatment with DAPA reduced HbA1c level by 1.2%±0.8%. Moreover, a significant decrease was observed in all subgroups: add-on to MET, −1.2%±0.7%; add-on to MET+DPP4i, −1.4%±0.8%; switched from SU, −1.4%±0.7%; switched from DPP4i, −0.5%±0.7%; and switched from TZD, −1.2%±0.9% (P<0.01). A significant decrease in body weight (−3.1±2.6 kg, P<0.001) was observed after DAPA administration. Estimated glomerular filtration rate and urine microalbumin were significantly decreased after 6 months of treatment with DAPA (−4.0±13.5 mL/min/1.73 m2, P=0.03; −23.6±45.9 mg/L, P<0.001).ConclusionTreatment with DAPA, whether added to or switched from other glucose-lowering agents, significantly decreased HbA1c levels in Korean patients with type 2 diabetes who visited a single primary diabetes clinic. DAPA can be considered as an optimal second-line treatment for patients with type 2 diabetes, as supported by real-world evidence studies.

show abstract

Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus

Cited by 13 publications

References 20 publications

1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 diabetes mellitus

1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 diabetes mellitus

Clinical Efficacy of Quadruple Oral Therapy for Type 2 Diabetes in Real-World Practice: A Retrospective Observational Study

Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea

Contact Info

Product

Resources

About